BiotechTube

Raludotatug Deruxtecan (R-DXd)

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Cancer

Conditions

Gastrointestinal Cancer

Trial Timeline

Apr 1, 2025 → Jan 4, 2029

NCT ID
NCT06864169

About Raludotatug Deruxtecan (R-DXd)

Raludotatug Deruxtecan (R-DXd) is a phase 2 stage product being developed by Daiichi Sankyo for Gastrointestinal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06864169. Target conditions include Gastrointestinal Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06864169Phase 2Active

Competing Products

20 competing products in Gastrointestinal Cancer

See all competitors
ProductCompanyStageHype Score
Patritumab deruxtecanDaiichi SankyoPhase 1/2
41
DS-6157aDaiichi SankyoPhase 1
33
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
52
Naldemedine + PlaceboShionogiPhase 2
52
GemcitabineEli LillyPhase 1/2
41
OlaratumabEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 2
52
cetuximabEli LillyPhase 2
52
BBI503Sumitomo PharmaPhase 2
52
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
41
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
52
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
77
FamitinibJiangsu Hengrui MedicinePhase 2
52
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
77
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
77
EsomeprazoleAstraZenecaPhase 3
77
AZD2171AstraZenecaPhase 2
52
EsomeprazoleAstraZenecaPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85